Categorynews

Viela Bio Closes $75 Million Series B Financing

June 17, 2019 Off By BusinessWire

Funding to support regulatory filing and pre-commercial planning for
lead product candidate, inebilizumab, and to advance development of
additional clinical candidates targeting autoimmune and inflammatory
diseases

Financing led by HBM Healthcare Investments

GAITHERSBURG, Md.–(BUSINESS WIRE)–Viela Bio today announced the successful completion of a $75 million
private placement of its Series B preferred stock, bringing the total
capital raised since the Company’s launch in February 2018 to more than
$300 million. The financing round was led by HBM Healthcare Investments,
and additional new investors participating included Viking Global
Investors, Cormorant Asset Management, Terra Magnum Capital Partners,
Goldman Sachs, and Barer & Son Capital. Existing investors participating
included Temasek.

“We are pleased that our ongoing development of our clinical programs
continues to attract capital from leading healthcare investors. This
financing will support our upcoming regulatory milestone—the anticipated
filing of our Biologics License Application with the U.S. FDA for our
lead product candidate, inebilizumab, for the treatment of neuromyelitis
optica spectrum disorder, or NMOSD,” said Bing Yao, Ph.D. Executive
Chairman and Chief Executive Officer. “NMOSD is a severe, debilitating,
and sometimes fatal neurological disease for which there is currently no
approved treatment. While our priority is to serve this patient
population through the successful approval and launch of inebilizumab,
we believe this financing also puts us in a strong position to pursue
additional new indications with inebilizumab. Furthermore, we believe
this financing will allow us to advance the entirety of our clinical
pipeline, which is comprised of several additional clinical candidates
for a range of rare autoimmune and inflammatory diseases.”

About Viela Bio

Viela Bio, headquartered in Gaithersburg, Maryland, is a clinical-stage
biotechnology company pioneering and advancing treatments for severe
inflammation and autoimmune diseases by selectively targeting shared
critical pathways that are the root cause of disease.

For more information, please visit www.vielabio.com.